Pulmatrix (DE:2PU)
FRANKFURT:2PU
2PU Stock Chart & Stats
€1.95
€0.05(0.85%)
At close: 4:00 PM EST
€1.95
€0.05(0.85%)
Day’s Range― - ―
52-Week Range€0.87 - €7.34
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.43M
Enterprise Value€2.12M
Total Cash (Recent Filing)€3.32M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding3,652,285
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.14
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.9
Revenue Forecast (FY)€13.95M
Bulls Say, Bears Say
Bulls Say
Low LeveragePulmatrix has no reported debt across recent periods, a durable financial advantage that reduces bankruptcy risk and interest burden. For a cash-burning clinical-stage biotech, zero leverage preserves flexibility to prioritize R&D or restructure during the merger, lowering fixed financial obligations over months.
Strategic Merger & CapitalThe planned all-stock merger to become Eos SENOLYTIX is a structural pivot: it brings new leadership, an AI-driven peptide platform, and ~ $19M in committed financings. This materially reshapes the business model, strengthens near-term funding for clinical milestones and repositions the firm into gerotherapeutics long-term.
Proprietary Delivery TechnologyPulmatrix’s core proprietary pulmonary delivery technology and clinical-stage inhaled candidates constitute enduring intellectual property and development assets. These capabilities enable differentiated product approaches, potential licensing or partnership opportunities, and sustained competitive positioning in respiratory drug delivery.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicates ongoing financing dependence; even with improvement from peak burn years, the company lacks internal cash generation to fund development. Over the next several months this elevates runway and dilution risk absent reliable external funding or revenue.
No Sustained RevenueThe absence of recurring revenue means the business is not generating operating cash from products, leaving R&D and operations reliant on capital markets and partners. This structural revenue gap increases execution and funding risk and makes long-term planning and investment contingent on successful deal execution.
Eroded Equity And AssetsSharp declines in shareholders' equity and total assets reflect cumulative losses and shrinking financial cushion. Reduced asset and equity bases limit strategic flexibility, increase susceptibility to dilution in future financings, and constrain the ability to absorb setbacks during clinical development or integration post-merger.
Pulmatrix News
2PU FAQ
What was Pulmatrix’s price range in the past 12 months?
Pulmatrix lowest stock price was €0.87 and its highest was €7.34 in the past 12 months.
What is Pulmatrix’s market cap?
Pulmatrix’s market cap is €4.43M.
When is Pulmatrix’s upcoming earnings report date?
Pulmatrix’s upcoming earnings report date is Aug 12, 2026 which is in 56 days.
How were Pulmatrix’s earnings last quarter?
Pulmatrix released its earnings results on May 15, 2026. The company reported -€0.276 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.276.
Is Pulmatrix overvalued?
According to Wall Street analysts Pulmatrix’s price is currently Overvalued.
Does Pulmatrix pay dividends?
Pulmatrix does not currently pay dividends.
What is Pulmatrix’s EPS estimate?
Pulmatrix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pulmatrix have?
Pulmatrix has 3,652,285 shares outstanding.
What happened to Pulmatrix’s price movement after its last earnings report?
Pulmatrix reported an EPS of -€0.276 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pulmatrix?
Currently, no hedge funds are holding shares in DE:2PU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pulmatrix
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.
Technical Analysis
Options Prices
Currently, No data available
---